The Announcement last week for success in POHs Oxymorphone Multi Dose trial was as stated by CEO Harry Rosen the most important milestone in POHs history.
•Oxymorphone patch achieves world first therapeutic plasma concentrations in all subjects in clinical trial
•Results from Phase 1 oxymorphone patch clinical trial demonstrates excellent drug delivery profile
•Most commercially significant trial result ever achieved by Phosphagenics as it proves the concept for an estimated $1 billion annual sales.
There are very few biotechs in Aust that are targeting such high value markets as POHs Pain Patch Portfolio. With this OxyM patch alone POH is expecting to achieve peak sales bn $.5 Billion and $1.5 Billion. POH has also with this result messaged the market that it is now at the cutting edge of Global Patch design which may lead to some unexpected commercial opportunities not previously considered.
I believe POH is today a greatly derisked company with extraordinary near term commercial prospects. What a year we have in store for 2014.
From todays course of trades it is clear others in the market agree.
Great to see POH recover from its recent lows and now chart a renewed course toward success under Harry Rosens stewardship. Congratulations to all the POH staffers for this magnificent clinical result.
the new poh
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $16.54K | 5.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 96791453 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 58594028 | 16 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |